Key filings, court orders, and procedural shifts shaping the GLP-1 litigation in 2025. Counts are for MDL 3094 unless noted.
Filing Counts & Growth
- Dec 5, 2025: MDL approaches ~3,000 cases; NAION filings accelerating.
- Nov 3, 2025: 2,914 cases; +100 in October.
- Oct 1, 2025: 2,809 cases; +133 in September.
- Sep 2, 2025: 2,676 cases; nearly +500 in August alone.
- Aug 1, 2025: 2,190 cases filed.
- Jul 1, 2025: 1,997 cases filed.
Key Court Orders & Motions
- Oct 31, 2025: Court sets schedule — expert discovery due Mar 27, 2026; summary judgment by Apr 16, 2026; first bellwethers expected mid-2026.
- Sep 6, 2025: Judge Gene E.K. Marston clarifies allowed claims: NAION (optic nerve ischemia) and objectively confirmed gastroparesis.
- Aug 19, 2025: Plaintiffs alleging gastroparesis must provide gastric emptying studies; claims without objective testing may be excluded.
- Sep 11, 2025: Lilly moves to centralize all NAION vision-loss cases into MDL 3094 (or a parallel MDL).
Enforcement & Industry Actions
- Aug 4, 2025: Novo Nordisk sues 12 defendants, including pharmacies, over compounded semaglutide products sold without FDA approval.
Why It Matters
- Scope expansion: Litigation is shifting from GI-only claims toward NAION vision-loss allegations.
- Evidence threshold: Gastric emptying studies now essential for gastroparesis claims.
- Trial horizon: Bellwether trials targeted for late 2026–early 2027.